Arrayed primer extension resequencing of mutations in the TP53 tumor suppressor gene: Comparison with denaturing HPLC and direct sequencing

Clinical Chemistry

Volumn 51, Issue 7, 2005, Pages 1284-1287

  Le Calvez, Florence ^a   Ahman, Aune ^b   Tonisson, Neeme ^b,c   Lambert, Jeremy ^a   Temam, Stéphane ^d   Brennan, Paul ^a   Zaridze, David G ^e   Metspalu, Andres ^b,c   Hainaut, Pierre ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b Asper Biotech Ltd   (Estonia)

^c UNIVERSITY OF TARTU   (Estonia)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Cancer Research Center   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; PRIMER DNA;

ARTICLE; BREAST TUMOR; CANCER DIAGNOSIS; CANCER SURVIVAL; CODON; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA SEQUENCE; GENE DELETION; GENE INSERTION; GENE MAPPING; GENE MUTATION; GENE PROBE; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; CELL LINE; COMPARATIVE STUDY; DNA MICROARRAY; GENETICS; LUNG TUMOR; MOUTH TUMOR; MUTATION; SENSITIVITY AND SPECIFICITY;

CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA PRIMERS; GENES, P53; HUMANS; LUNG NEOPLASMS; MOUTH NEOPLASMS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 23444431651     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.048348     Document Type: Article

References (24)

1. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137.
2. Bergamaschi D, Gasco M, Miller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402.
3. Schneider PM, Stoeltzing O, Roth JA, Hoelscher AH, Wegerer S, Mizumoto S, et al. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Cancer Res 2000;6:3153-8.
4. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2002;99:597-602.
5. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.
6. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
7. Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995;14:71-5.
8. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-12.
9. Kristensen VN, Kelefiotis D, Kristensen T, Borresen-Dale AL. High-throughput methods for detection of genetic variation. Biotechniques 2001;30: 318-22, 324, 326.
10. Hacia JG. Resequencing and mutational analysis using oligonucleotide microarrays. Nat Genet 1999;21:42-7.
11. Wikman FP, Lu ML, Thykjaer T, Olesen SH, Andersen LD, Cordon-Cardo C, et al. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem 2000;46: 1555-61.
12. Kurg A, Tonisson N, Georgiou I, Shumaker J, Tollett J, Metspalu A. Arrayed primer extension: solid-phase four-color DNA resequencing and mutation detection technology. Genet Test 2000;4:1-7.
13. Tonisson N, Zernant J, Kurg A, Pavel H, Slavin G, Roomere H, et al. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci U S A 2002;99:5503-8.
14. Dai M, Clifford GM, Le Calvez F, Castellsague X, Snijders PJ, Pawlita M, et al. Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res 2004;64:468-71.
15. Guo Z, Guilfoyle RA, Thiel AJ, Wang R, Smith LM. Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports. Nucleic Acids Res 1994;22:5456-65.
16. Rosenblum BB, Lee LG, Spurgeon SL, Khan SH, Menchen SM, Heiner CR, et al. New dye-labeled terminators for improved DNA sequencing patterns. Nucleic Acids Res 1997;25:4500-4.
17. Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A 1999;96:7382-7.
18. Tonisson N, Kurg A, Kaasik K, Lohmussaar E, Metspalu A. Unravelling genetic data by arrayed primer extension. Clin Chem Lab Med 2000;38: 165-70.
19. Bosch FX, Ritter D, Enders C, Flechtenmacher C, Abel U, Dietz A, et al. Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer 2004;111:530-8.
20. Wen WH, Bernstein L, Lescallett J, Beazer-Barclay Y, Sullivan-Halley J, White M, et al. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res 2000;60: 2716-22.
21. McGregor JM, Harwood CA, Brooks L, Fisher SA, Kelly DA, O'nions J, et al. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 2002;119:84-90.
22. Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 1997;4:239-45.
23. Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, et al. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003;9:4860-4.
24. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23:3328-37.